Cassimatis Maree, Browne Gary, Orr Rhonda
Discipline of Exercise and Sports Science, Faculty of Medicine and Health, Sydney School of Health Sciences, The University of Sydney, Sydney, Australia.
Sydney Children's Hospital Network, Children's Hospital Institute of Sports Medicine, Children's Hospital Westmead, Sydney, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, The University of Sydney, Sydney, Australia.
Arch Phys Med Rehabil. 2023 Feb;104(2):340-349. doi: 10.1016/j.apmr.2022.09.018. Epub 2022 Oct 13.
To investigate the utility of melatonin supplementation as a treatment option for individuals with sleep disturbance after traumatic brain injury (TBI).
A systematic search was conducted in 6 electronic databases (Medline, AMED, CINAHL, Embase, Scopus, and SPORTDiscus) from earliest records to April 2022.
Studies were eligible for inclusion if they met the following criteria: a) human participants with sleep disturbance after TBI, b) melatonin or melatonergic agent used as an intervention to treat sleep disturbance, and c) outcomes of melatonin administration reported. All TBI severity types (mild, moderate, and severe) were eligible. The initial search retrieved a total of 595 articles, with 9 studies meeting the eligibility criteria.
Two reviewers independently extracted data from eligible studies and assessed methodological quality. Extracted data consisted of participant and injury characteristics, melatonin interventional properties, and sleep outcome. Methodological quality was assessed via the Downs and Black checklist.
A total of 251 participants with TBI-induced sleep disturbance (mean age range: 14.0-42.5 years) were included. Melatonin, Circadin (prolonged-release melatonin), or Ramelteon (melatonin receptor agonist) were administered. Dosages and intervention duration ranged from 2 to 10 mg and 3 to 12 weeks, respectively. Eight out of 9 studies reported positive outcomes after melatonin treatment. Significant improvements in subjective sleep quality, objective sleep efficiency, and total sleep time were found with melatonin. Reductions in self-reported fatigue, anxiety, and depressive symptoms were also observed with melatonin treatment. No serious adverse events were reported after melatonin administration.
Melatonin has good tolerability after short-term use and the potential to be a therapeutic agent for those with sleep disturbance after TBI. Melatonin was shown to be beneficial to sleep quality, sleep duration, and sleep efficiency. Additional clinically relevant outcomes of improved mental health suggest that melatonin use may be a promising treatment option for individuals experiencing co-occurring disorders of mood and sleep disturbance post-injury.
探讨补充褪黑素作为创伤性脑损伤(TBI)后睡眠障碍患者的一种治疗选择的效用。
对6个电子数据库(Medline、AMED、CINAHL、Embase、Scopus和SPORTDiscus)从最早记录到2022年4月进行了系统检索。
符合以下标准的研究纳入本研究:a)TBI后有睡眠障碍的人类参与者;b)使用褪黑素或褪黑素能药物作为治疗睡眠障碍的干预措施;c)报告了褪黑素给药的结果。所有TBI严重程度类型(轻度、中度和重度)均符合条件。初步检索共获得595篇文章,其中9项研究符合纳入标准。
两名评审员独立从符合条件的研究中提取数据并评估方法学质量。提取的数据包括参与者和损伤特征、褪黑素干预特性和睡眠结果。通过唐斯和布莱克检查表评估方法学质量。
共纳入251例TBI引起睡眠障碍的参与者(平均年龄范围:14.0 - 42.5岁)。给予褪黑素、Circadin(缓释褪黑素)或雷美替胺(褪黑素受体激动剂)。剂量和干预持续时间分别为2至10毫克和3至12周。9项研究中有8项报告了褪黑素治疗后的阳性结果。褪黑素治疗后,主观睡眠质量、客观睡眠效率和总睡眠时间有显著改善。褪黑素治疗还观察到自我报告的疲劳、焦虑和抑郁症状减轻。褪黑素给药后未报告严重不良事件。
褪黑素短期使用后耐受性良好,有可能成为TBI后睡眠障碍患者的治疗药物。褪黑素被证明对睡眠质量、睡眠时间和睡眠效率有益。心理健康改善的其他临床相关结果表明,对于受伤后同时出现情绪障碍和睡眠障碍的个体,使用褪黑素可能是一种有前景的治疗选择。